Close Menu
August 27, 2020
Sponsored by
Cellecta

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

GenomeWebinar

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy. Of those, 40 percent also harbor mutations in the PIK3CA gene, and are targeted by the PI3K-alpha inhibitor alpelisib (Novartis' Piqray). However, intrinsic and adaptive drug resistance is the norm with these agents and mechanisms of resistance are still largely unknown in the clinic.

In this webinar, Guotai Xu of Memorial Sloan Kettering Cancer Center will discuss results of CRISPR/Cas9 screens that he has run which suggest endocrine therapy and PI3K-alpha inhibitor resistance occurs  and may provide a basis to develop resistance therapeutic strategies to prevent or revert this resistance. Dr. Xu will share details of work in this area that was published in Nature in January 2020.

Sponsored by

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Apr
22
Sponsored by
10x Genomics

The human immune system is extremely complex, comprised of multiple cell types and states interacting in myriad ways to produce diverse cellular ecosystems.